Relationship between anxiety and serotonin in the ventral striatum

NeuroReport

Volumn 9, Issue 6, 1998, Pages 1025-1029

  Schwarting, Rainer K W ^a   Thiel, Christiane M ^a   Müller, Christian P ^a   Huston, Joseph P ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Amygdala; Anxiety; Dopamine; Emotionality; Frontal cortex; Hippocampus; Open field; Plus maze; Serotonin; Striatum

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; NORADRENALIN; SEROTONIN; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; MALE; MAZE TEST; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT;

EID: 0032550136     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199804200-00013     Document Type: Article

References (27)

1. Lister RG. Psychopharmacology 92, 180-185 (1987).
2. Rodgers RJ and Cole JC. The elevated plus-maze: pharmacology, methodology and ethology. In: Cooper SJ and Hendrie CA, eds. Ethology and Psychopharmacology. London: Wiley, 1995: 9-44.
3. Dawson GR and Tricklebank MD. Trends Pharmacol Sci 16, 33-37 (1995).
4. Iversen SD. Neuropharmacology 23, 1553-1560 (1984).
5. Graeff FG, Guimaraes FS, de Andrade TGCS and Deakin JFW. Pharmacol Biochem Behav 54, 129-141 (1996).
6. Hogg S. Pharmacol Biochem Behav 54, 21-30 (1996).
7. Chaouloff F, Castanon N and Mormède P. Neurosci Lett 182, 217-221 (1994).
8. Rex A, Sondern U, Voigt JP et al. Pharmacol Biochem Behav 54, 107-111 (1996).
9. Pich EM and Samanin R. Psychopharmacology 89, 125-130 (1986).
10. Rex A, Marsden CA and Fink H. Psychopharmacology 110, 490-496 (1993).
11. Rodgers RJ, Cao B-J, Dalvi A and Holmes A. Brazil J Med Biol Res 30, 289-304 (1997).
12. Schwarting RKW, Goldenberg R, Steiner H et al. J Neurosci Meth 49, 199-210 (1993).
13. Schwarting RKW and Huston JP. Neuropharmacology 26, 457-461 (1987).
14. Driscoll P, Dedek K, Martin JR and Bättig K. Eur J Pharmacol 68, 373-376 (1980).
15. Kulikov A, Castanon N, Mormède P and Chaouloff F. Psychopharmacology 121, 385-395 (1995).
16. Charney Y, Steimer T, Huguenin C and Driscoll P. Neurosci Res Commun 16, 29-35 (1995).
17. Willner P and Scheel-Krüger J. The Mesolimbic Dopamine System: From Motivation to Action. Chichester: Wiley, 1991.
18. Carter CJ and Pycock CJ. Naunyn-Schmiedeberg's Arch Pharmacol 3O8, 51-54 (1979).
19. Schwarting RKW and Carey RJ. Behav Brain Res 18, 279-283 (1985).
20. Duncan GE, Knapp DJ and Breese GR. Brain Res 713, 79-91 (1996).
21. Zangen A, Overstreet DH and Yadid G. J Neurochem 69, 2477-2483 (1997).
22. Treit D, Menard J and Royan C. Pharmacol Biochem Behav 44, 463-469 (1993).
23. Rodgers RJ, Johnson NJT, Carr J and Hodgson TP. Behav Brain Res 86, 71-77 (1997).
24. Rodgers RJ, Lee C and Shepherd JK. Psychopharmacology 106, 102-110 (1992).
25. File SE, Zangrossi H Jr, Viana M and Graeff FG. Psychopharmacology 111, 491-494 (1993).
26. File SE, Andrews N et al. Eur J Pharmacol 218, 9-14 (1992).
27. File SE. Psychopharmacology 100, 281-282 (1990).